Allena Pharmaceuticals, Inc. Consolidated Net Income/Loss

Consolidated Net Income/Loss of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Consolidated Net Income/Loss growth rates and interactive chart.


Highlights and Quick Summary

  • Consolidated Net Income/Loss for the quarter ending March 31, 2022 was $-11.8 Million (a 13.99% increase compared to previous quarter)
  • Year-over-year quarterly Consolidated Net Income/Loss decreased by -15.45%
  • Annual Consolidated Net Income/Loss for 2021 was $-48.7 Million (a 48.16% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2020 was $-32.8 Million (a -30.62% decrease from previous year)
  • Annual Consolidated Net Income/Loss for 2019 was $-47.3 Million (a 32.8% increase from previous year)
  • Twelve month Consolidated Net Income/Loss ending March 31, 2022 was $-48.8 Million (a 0.36% increase compared to previous quarter)
  • Twelve month trailing Consolidated Net Income/Loss increased by 11.27% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-48.8 Million $-48.7 Million $-48.6 Million $-43.9 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Consolidated Net Income/Loss of Allena Pharmaceuticals, Inc.

Most recent Consolidated Net Income/Lossof ALNA including historical data for past 10 years.

Interactive Chart of Consolidated Net Income/Loss of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-11.81
2021 $-10.36 $-12.69 $-13.97 $-11.64 $-48.66
2020 $-10.26 $-8.03 $-6.98 $-7.59 $-32.85
2019 $-11.36 $-13.29 $-11.27 $-11.42 $-47.34
2018 $-9.61 $-9.51 $-8.65 $-7.88 $-35.65
2017 $-6.68 $-4.67 $-4.63 $-5.67 $-21.65
2016 $-6.14 $-24.51
2015 $-14.25

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.